School of Chemistry and Chemical Engineering, Nantong University, 9 Seyuan Rd, Nantong 226019, P. R. China.
CNS Neurol Disord Drug Targets. 2014 Feb;13(1):166-72. doi: 10.2174/18715273113129990076.
Abnormal interactions of Zn(2+) and Cu(2+) with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer's disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer's disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn(2+) or Cu(2+)-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.
锌离子(Zn(2+))和铜离子(Cu(2+))与淀粉样 β 肽(Aβ)的异常相互作用被认为在阿尔茨海默病(AD)的神经发病机制中起重要作用。金属螯合剂是 AD 的潜在治疗剂,因为它们可以从 Aβ 聚集物中螯合金属离子并逆转聚集。在这项研究中,两种含氮配体,TACN 和 BPA,被研究为治疗阿尔茨海默病的可能金属螯合剂。通过浊度法、硫黄素 T(ThT)荧光光谱法、电感耦合等离子体质谱法(ICP-MS)、BCA 蛋白测定法、圆二色光谱法(CD)和原子力显微镜(AFM)研究了螯合剂与 Aβ40 聚集物之间的相互作用。结果表明,TACN 和 BPA 既能破坏又能阻止 Zn(2+)或 Cu(2+)-诱导的 Aβ40 聚集。此外,它们还可以抑制 Cu-Aβ40 诱导的 H2O2 的产生,这与 AD 中的毒性氧化应激有关。